Semi-Rational Screening of Probiotics from the Fecal Flora of Healthy Adults against DSS-Induced Colitis Mice by Enhancing Anti-Inflammatory Activity and Modulating the Gut Microbiota

J Microbiol Biotechnol. 2019 Sep 28;29(9):1478-1487. doi: 10.4014/jmb.1807.06061.

Abstract

Ulcerative colitis (UC), a chronic inflammatory bowel disease, substantially impacts patients' health-related quality of life. In this study, an effective strategy for discovering high-efficiency probiotics has been developed. First, in order to survive in the conditions of the stomach and intestine, high bile salt-resistant and strong acid-resistant strains were screened out from the fecal flora of healthy adults. Next, the probiotic candidates were rescreened by examining the induction ability of IL-10 (anti-inflammatory factor) production in dextran sodium sulfate (DSS)-induced colitis mice, and Lactobacillus sakei 07 (L07) was identified and selected as probiotic P. In the end, fourteen bifidobacterium strains isolated from stools of healthy males were examined for their antimicrobial activity. Bifidobacterium bifidum B10 (73.75% inhibition rate) was selected as probiotic B. Moreover, the colonic IL-6 and TNF-α expression of the DSSinduced colitis mice treated with L. sakei 07 (L07) - B. bifidum B10 combination (PB) significantly decreased and the IL-10 expression was up-regulated by PB compared to the DSS group. Furthermore, Bacteroidetes and Actinobacteria decreased and Firmicutes increased in the DSS group mice, significantly. More interestingly, the intestinal flora biodiversity of DSS colitis mice was increased by PB. Of those, the level of B. bifidum increased significantly. The Bacteriodetes/Firmicutes (B/F) ratio increased, and the concentration of homocysteine and LPS in plasma was down-regulated by PB in the DSS-induced colitis mice. Upon administration of PB, the intestinal permeability of the the DSS-induced colitis mice was decreased by approximately 2.01-fold. This method is expected to be used in high-throughput screening of the probiotics against colitis. In addition, the L. sakei 07 - B. bifidum B10 combination holds potential in UC remission by immunomodulatory and gut microbiota modulation.

Keywords: Probiotics; anti-inflammatory; gut microbiota; immunomodulatory; ntestinal permeability; ulcerative colitis.

MeSH terms

  • Adult
  • Animals
  • Anti-Inflammatory Agents / isolation & purification
  • Anti-Inflammatory Agents / metabolism
  • Anti-Inflammatory Agents / pharmacology
  • Anti-Inflammatory Agents / therapeutic use
  • Bacteria / classification
  • Bacteria / genetics
  • Bacteria / growth & development
  • Bifidobacterium bifidum / isolation & purification
  • Bifidobacterium bifidum / metabolism
  • Biodiversity
  • Colitis / chemically induced
  • Colitis / drug therapy*
  • Colitis / microbiology
  • Colon / immunology
  • Colon / metabolism
  • Colon / pathology
  • Cytokines / metabolism
  • Dextran Sulfate / toxicity
  • Disease Models, Animal
  • Feces / chemistry
  • Feces / microbiology*
  • Gastrointestinal Microbiome / drug effects*
  • High-Throughput Screening Assays
  • Homocysteine / analysis
  • Homocysteine / blood
  • Humans
  • Immunologic Factors / isolation & purification
  • Immunologic Factors / metabolism
  • Immunologic Factors / pharmacology
  • Immunologic Factors / therapeutic use
  • Intestinal Mucosa / metabolism
  • Intestinal Mucosa / microbiology
  • Latilactobacillus sakei / isolation & purification
  • Latilactobacillus sakei / metabolism
  • Lipopolysaccharides / analysis
  • Lipopolysaccharides / blood
  • Male
  • Mice, Inbred C57BL
  • Permeability / drug effects
  • Probiotics / isolation & purification
  • Probiotics / metabolism
  • Probiotics / therapeutic use*

Substances

  • Anti-Inflammatory Agents
  • Cytokines
  • Immunologic Factors
  • Lipopolysaccharides
  • Homocysteine
  • Dextran Sulfate